Cribb Alastair E, Knight M Joy, Dryer Dagny, Guernsey Judy, Hender Kimberly, Tesch Marvin, Saleh Tarek M
Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Edward Island, 550 University Avenue, Charlottetown, Prince Edward Island, Canada C1A 4P3.
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):551-8. doi: 10.1158/1055-9965.EPI-05-0801.
Estrogen and its metabolites are believed to play important roles in breast cancer. The influence of genetic polymorphisms in the enzymes responsible for formation and disposition of estrogen on breast cancer risk may shed light on the importance of estrogen metabolites in this disease. However, for such studies to be valid, it is important to correctly identify the enzymes involved in estrogen bioactivation. Therefore, we assessed the human cytochrome P450-dependent oxidation of estrone using substrate concentrations that more closely approximate the maximum expected concentrations in breast tissue. The in vitro metabolism of estrone by recombinant human cytochrome P450 enzymes and human liver microsomes was studied. The formation of estrone metabolites (2-hydroxyestrone, 4-hydroxyestrone, and 16alpha-hydroxyestrone) was monitored by high-performance liquid chromatography. 2-Hydroxyestrone formation was catalyzed predominantly by CYP1A2, CYP1A1, and CYP1B1 enzymes; 4-hydroxyestrone formation was catalyzed predominantly by CYP1B1, CYP1A2, and CYP1A1 enzymes; and 16alpha-hydroxyestrone formation was catalyzed predominantly by CYP2C19, CYP1A1, and CYP3A5. This study confirms the important role of members of the CYP1 family in the 2-hydroxylation and 4-hydroxylation of estrone, but the enzymes identified as responsible for the 16alpha-hydroxylation of estrone are different from those previously identified. The relative importance of these enzymes in vivo would depend on the specific tissue expression of the enzymes. These enzymes are all known to be genetically variant in the human population, and additional studies to assess the role CYP1A2, CYP2C19, and CYP3A5 in breast cancer risk are indicated.
雌激素及其代谢产物被认为在乳腺癌中发挥重要作用。负责雌激素生成和代谢的酶的基因多态性对乳腺癌风险的影响,可能有助于揭示雌激素代谢产物在该疾病中的重要性。然而,为使此类研究有效,正确识别参与雌激素生物活化的酶至关重要。因此,我们使用更接近乳腺组织中预期最大浓度的底物浓度,评估了人细胞色素P450依赖的雌酮氧化。研究了重组人细胞色素P450酶和人肝微粒体对雌酮的体外代谢。通过高效液相色谱监测雌酮代谢产物(2-羟基雌酮、4-羟基雌酮和16α-羟基雌酮)的形成。2-羟基雌酮的形成主要由CYP1A2、CYP1A1和CYP1B1酶催化;4-羟基雌酮的形成主要由CYP1B1、CYP1A2和CYP1A1酶催化;16α-羟基雌酮的形成主要由CYP2C19、CYP1A1和CYP3A5催化。本研究证实了CYP1家族成员在雌酮2-羟化和4-羟化中的重要作用,但被确定为负责雌酮16α-羟化的酶与先前确定的酶不同。这些酶在体内的相对重要性将取决于酶的特定组织表达。众所周知,这些酶在人群中都存在基因变异,因此需要进行更多研究来评估CYP1A2、CYP2C19和CYP3A5在乳腺癌风险中的作用。